Astellas Pharma has agreed to acquire privately-held Belgian drug discovery group Odega in a deal worth up to 800 million Euros.
Ogeda is a clinical-stage drug discovery company that discovers and develops small molecule drugs targeting G-protein coupled receptors (GPCRs).
The firm’s lead investigational candidate is fezolinetant, a selective NK3 receptor antagonist with positive data from a Phase IIa study for the non-hormonal treatment of menopause-related vasomotor symptoms.
Under the deal, Astellas will make an initial payment of 500 million euros in consideration of 100 percent of the equity in Ogeda at the closing of the transaction.
Ogeda shareholders are also eligible to receive an additional 300 million euros with attainment of certain clinical development and regulatory milestones for fezolinetant.
If the transaction, which remains subject to certain conditions, is successfully completed, Ogeda will become a wholly owned subsidiary of Astellas, expanding the Japanese drugmaker’s late-stage pipeline and contributing to its mid-to-long term growth.
By Selina McKee
Source: Pharma Times
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.